Royal Bank of Canada’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$433K Buy
5,307
+1,444
+37% +$104K ﹤0.01% 4473
2026
Q1
$263K Sell
3,863
-2,378
-38% -$168K ﹤0.01% 4538
2025
Q4
$474K Sell
6,241
-92,638
-94% -$6.73M ﹤0.01% 4205
2025
Q3
$6.07M Sell
98,879
-173,460
-64% -$9.03M ﹤0.01% 2511
2025
Q2
$13.3M Buy
272,339
+270,503
+14,733% +$12.8M ﹤0.01% 1824
2025
Q1
$93K Sell
1,836
-1,704
-48% -$85K ﹤0.01% 5270
2024
Q4
$159K Sell
3,540
-4,879
-58% -$209K ﹤0.01% 5001
2024
Q3
$313K Buy
8,419
+1,206
+17% +$40.4K ﹤0.01% 4470
2024
Q2
$221K Buy
7,213
+4,419
+158% +$143K ﹤0.01% 4682
2024
Q1
$81K Sell
2,794
-18,868
-87% -$529K ﹤0.01% 5307
2023
Q4
$597K Buy
21,662
+11,787
+119% +$270K ﹤0.01% 4118
2023
Q3
$222K Buy
9,875
+3,436
+53% +$128K ﹤0.01% 4697
2023
Q2
$261K Sell
6,439
-3,642
-36% -$178K ﹤0.01% 4513
2023
Q1
$488K Sell
10,081
-5,437
-35% -$249K ﹤0.01% 3884
2022
Q4
$592K Buy
15,518
+11,239
+263% +$467K ﹤0.01% 3958
2022
Q3
$215K Sell
4,279
-1,279
-23% -$62.7K ﹤0.01% 4711
2022
Q2
$222K Sell
5,558
-11,884
-68% -$417K ﹤0.01% 4734
2022
Q1
$651K Sell
17,442
-11,559
-40% -$445K ﹤0.01% 4052
2021
Q4
$1.16M Buy
29,001
+1,954
+7% +$74.8K ﹤0.01% 3661
2021
Q3
$1.01M Sell
27,047
-655
-2% -$26.9K ﹤0.01% 3689
2021
Q2
$1.17M Buy
27,702
+7,421
+37% +$318K ﹤0.01% 3510
2021
Q1
$961K Buy
20,281
+8,543
+73% +$507K ﹤0.01% 3625
2020
Q4
$717K Sell
11,738
-737
-6% -$43.4K ﹤0.01% 3818
2020
Q3
$583K Sell
12,475
-96
-0.8% -$4.73K ﹤0.01% 3731
2020
Q2
$637K Buy
12,571
+2,326
+23% +$114K ﹤0.01% 3569
2020
Q1
$457K Sell
10,245
-17,422
-63% -$877K ﹤0.01% 3696
2019
Q4
$1.33M Buy
27,667
+1,348
+5% +$57.3K ﹤0.01% 3227
2019
Q3
$890K Sell
26,319
-2,403
-8% -$105K ﹤0.01% 3440
2019
Q2
$1.29M Sell
28,722
-7,614
-21% -$301K ﹤0.01% 3100
2019
Q1
$1.37M Sell
36,336
-9,013
-20% -$303K ﹤0.01% 2959
2018
Q4
$1.56M Buy
45,349
+6,510
+17% +$234K ﹤0.01% 2828
2018
Q3
$1.82M Buy
38,839
+12,099
+45% +$501K ﹤0.01% 2910
2018
Q2
$902K Buy
26,740
+26,540
+13,270% +$828K ﹤0.01% 3302
2018
Q1
$5K Sell
200
-529
-73% -$13.4K ﹤0.01% 5932
2017
Q4
$12K Sell
729
-10,243
-93% -$173K ﹤0.01% 5800
2017
Q3
$219K Buy
10,972
+10,209
+1,338% +$200K ﹤0.01% 4452
2017
Q2
$14K Sell
763
-2,920
-79% -$39.3K ﹤0.01% 5683
2017
Q1
$36K Buy
3,683
+1,122
+44% +$13.6K ﹤0.01% 5323
2016
Q4
$28K Buy
2,561
+519
+25% +$5.45K ﹤0.01% 5579
2016
Q3
$29K Sell
2,042
-2,223
-52% -$18.1K ﹤0.01% 5397
2016
Q2
$30K Sell
4,265
-4,866
-53% -$35.7K ﹤0.01% 5335
2016
Q1
$60K Sell
9,131
-122,191
-93% -$2.12M ﹤0.01% 5023
2015
Q4
$4.26M Buy
131,322
+114,770
+693% +$3.38M ﹤0.01% 1969
2015
Q3
$442K Sell
16,552
-3,105
-16% -$133K ﹤0.01% 3635
2015
Q2
$946K Buy
19,657
+1,465
+8% +$85.5K ﹤0.01% 2971
2015
Q1
$1.11M Sell
18,192
-11,933
-40% -$728K ﹤0.01% 2780
2014
Q4
$1.56M Sell
30,125
-16,474
-35% -$725K ﹤0.01% 2533
2014
Q3
$2.05M Buy
46,599
+29,189
+168% +$913K ﹤0.01% 2281
2014
Q2
$455K Buy
17,410
+8,385
+93% +$179K ﹤0.01% 3491
2014
Q1
$236K Sell
9,025
-7,325
-45% -$197K ﹤0.01% 3969
2013
Q4
$277K Buy
16,350
+4,995
+44% +$87.8K ﹤0.01% 3893
2013
Q3
$244K Buy
+11,355
New +$197K ﹤0.01% 3944

Other funds holding PTCT

Royal Bank of Canada's PTCT Position: Q2 2026 in Review

Royal Bank of Canada increased its PTC Therapeutics (PTCT) stake by 37% in Q2 2026, buying an estimated $104K and bringing the position to 5,307 shares worth $433K. The position accounts for ﹤0.01% of the portfolio, ranked #4473.

Royal Bank of Canada first reported a position in PTCT in Q3 2013 and has held it in 52 quarters since. The position peaked at $13.3M in Q2 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Royal Bank of Canada held 5,307 shares of PTC Therapeutics worth $433K as of Q2 2026.
  • Royal Bank of Canada bought 1,444 PTC Therapeutics shares in Q2 2026, an estimated $104K.
  • PTC Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #4473 holding.
  • Royal Bank of Canada first reported a position in PTC Therapeutics in Q3 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's PTC Therapeutics position peaked at $13.3M in Q2 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.